Skip to content
TickerMagic

Panacea Biotec Limited

PANACEABIONSEHealthcare
₹352.85
-3.70 (-1.04%) · EOD 2026-11-20

Our verdict

Sell

Valuation (70/100) does the heavy lifting; momentum (6/100) is the drag.

Fair valueHealth A
Quality 34Momentum 6Value 70Trend 23The Spark ↓

Our fair value

Undervalued by 73%
₹611.18up 73.21%
Price ₹353Range ₹562 – ₹660

Buy-below (20% margin of safety): ₹488.95

The bottom line

TickerMagic rates Panacea Biotec Limited a Sell, scoring 37/100 on our blended model. The price is about 42% below its 52-week high of ₹607.75 and 19% above the low of ₹296.05. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9. It clears 4 of 11 investability checks, with durability 34, valuation 39 and momentum 6 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹611.18up 73.21%
Undervalued by 73%
Price ₹352.85Range ₹562.29–₹660.08
Relative multipleslow confidence

With a 20% margin of safety, our buy-below price is ₹488.95. Low-confidence estimate — limited data.

1-year price

EOD · 2026-11-20
1D
down 1.04%
1W
down 2.39%
1M
up 1.09%
3M
down 13.06%
6M
down 15.26%
1Y
—

52-week range

-41.94% from the 52-week high.

Trend check
Below 50-DMA₹356Below 200-DMA₹397

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Sell37
A
Financial health 100/100
Altman Z 6.3 · Safe zone

Piotroski F-score 2/9 — quality of earnings & balance sheet.

Our scores

Durability34
Valuation39
Momentum6

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 4 of 11 checks
Each check screens one fundamentals, valuation or trend signal.
  • No data: ROE above 15%
  • Pass: Low debt (D/E < 0.5): 0.03x
  • Fail: Positive free cash flow
  • Fail: Revenue growth > 10%: 1%
  • Fail: Earnings growing: -12%
  • Fail: Net margin ≥ 10%: -1.3%
  • No data: Current ratio > 1.5
  • Pass: Below our fair value
  • Pass: Margin of safety ≥ 20%
  • Fail: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 6.3
  • Fail: Piotroski ≥ 7: 2/9

Quarterly results

Revenue · 2Q2011
₹226 Cr
Net profit
₹17 Cr
Margin
7%
2Q2009
3Q2009
4Q2009
2Q2011
Revenue Net profitLatest revenue QoQ -1%

Annual financials

Revenue · 2012
₹711 Cr
Net profit
₹-164 Cr
Margin
-23%
2009
2010
2011
2012
Revenue Net profitLatest revenue YoY -38%

Shareholding

  • Promoter72.7%
  • Institutions0.1%
  • Public & other27.2%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹3,406 Cr
P/E ratio
—
P/B ratio
4.33
EPS (TTM)
₹-0.89
ROE
—
Debt / Equity
0.03x
Profit margin
-1.3%
Free cash flow
₹-37 Cr
52-week high
₹607.75
-41.94% from high
52-week low
₹296.05
Dividend yield
—
Beta
0.14
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 6.3.

Opportunities

  • Well off its 52-week high — possible mean-reversion.
  • Trades ~73% below our estimated fair value.

Bear case

Weaknesses

  • Price below its 200-day moving average (downtrend).
  • Weak Piotroski score (2/9).

Threats

  • Earnings contracting year on year.

About Panacea Biotec Limited

Panacea Biotec Limited develops and manufactures vaccines, pharmaceuticals, nutraceuticals, and nutrition products for domestic and international markets. Operating through vaccines and pharmaceutical formulations & nutrition divisions, the company offers prescription products across oncology, diabetes, gastro-intestinal care, nephrology, and orthopedic therapeutic areas.

Panacea Biotec Limited — frequently asked questions

Is Panacea Biotec Limited a buy, hold or sell?

TickerMagic currently rates Panacea Biotec Limited (PANACEABIO) a Sell, based on a blended score of 37/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Panacea Biotec Limited's fair value?

Our blended DCF and relative-valuation model estimates Panacea Biotec Limited's fair value at about ₹611.18, versus a current price of ₹352.85 — roughly 73% upside. On that basis the stock looks undervalued by 73%.

Is Panacea Biotec Limited financially healthy?

Panacea Biotec Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 2/9.

How has Panacea Biotec Limited's share price performed?

Panacea Biotec Limited is down 13% over three months, and last traded at ₹352.85. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.